Wyeth Pharmaceuticals

Huntercombe Lane South, Taplow, Maidenhead, Berks, SL6 0PH
Telephone: +44 (0)1628 604 377
Fax: +44 (0)1628 666 368
Medical Information Direct Line: +44 (0)845 367 0098
Medical Information e-mail: ukmedinfo@wyeth.com
Medical Information Fax: +44 (0)845 367 0777
Summary of Product Characteristics last updated on the eMC: 18/08/2009
SPC Enzira® Suspension for injection, pre-filled syringe/Influenza vaccine (split virion, inactivated) PH. Eur.

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 18/08/2009 and displayed until Current
Reasons for adding or updating:
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   11-Aug-2009
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Section 2 Vaccine updated to current season.
Updated on 12/09/2008 and displayed until 18/08/2009
Reasons for adding or updating:
  • Change to section 10 date of revision of the text
  • Change to section 2 - Qualitative and quantitative composition
Date of revision of text on the SPC:   01-Jun-2008
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Section 2: Annual Strain Update
Section 10: Date amended
Updated on 10/09/2007 and displayed until 12/09/2008
Reasons for adding or updating:
  • New SPC for new product

Active Ingredients/Generics

 
   influenza vaccine


© 2010 Datapharm Communications Ltd

Go to www.medicines.org.uk